GTBP GT Biopharma Inc

Price (delayed)

$0.4745

Market cap

$17.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.83

Enterprise value

$8.09M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform ...

Highlights
GT Biopharma's equity has increased by 31% QoQ
GT Biopharma's quick ratio has increased by 25% QoQ
GTBP's EPS has dropped by 161% year-on-year and by 122% since the previous quarter
The company's net income has shrunk by 68% QoQ

Key stats

What are the main financial stats of GTBP

GTBP stock price

How has the GT Biopharma stock price performed over time
Intraday
8.01%
1 week
6.53%
1 month
24.05%
1 year
-82.36%
YTD
-39.57%
QTD
16.27%

Financial performance

How have GT Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.34M
Net income
-$47.73M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 68% QoQ
GTBP's operating income is down by 7% since the previous quarter

Price vs fundamentals

How does GTBP's price correlate with its fundamentals

Growth

What is GT Biopharma's growth rate over time

Valuation

What is GT Biopharma stock price valuation
P/E
N/A
P/B
1.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GTBP's EPS has dropped by 161% year-on-year and by 122% since the previous quarter
The price to book (P/B) is 41% lower than the 5-year quarterly average of 3.1
GT Biopharma's equity has increased by 31% QoQ

Efficiency

How efficient is GT Biopharma business performance
The company's return on assets fell by 27% QoQ

Dividends

What is GTBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GTBP.

Financial health

How did GT Biopharma financials performed over time
The total liabilities has contracted by 34% YoY but it has grown by 4.2% from the previous quarter
GT Biopharma's quick ratio has increased by 25% QoQ
The debt is 100% lower than the equity
GT Biopharma's equity has increased by 31% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.